{"schema_version":"1.0","type":"article","title":"Off-the-Shelf CAR-T in 2026: Rebounding From the Trough","url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.md","lang":"en","date":"2026-07-06","publish_at":"2026-07-06T12:26:18+08:00","updated_at":"2026-07-06","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","cell therapy","CAR-T","allogeneic cell therapy","clinical data","drug development","autoimmune disease","biotech valuation"],"summary":"Off-the-shelf allogeneic CAR-T is no longer just a beautiful manufacturing story. In 2026, better clinical signals and clearer positioning are bringing the field back to the table.","key_points":[],"facts":[],"sections":["01｜Caribou’s vispa-cel: 17.1-Month PFS Puts Hope Back on the Table","02｜Allogene: Moving From Relapse Treatment Toward MRD-Positive Early Intervention","03｜Wugen: T-Cell Malignancies Remain One of the Hardest Tests","04｜The Value of Allogeneic CAR-T Is Not Only in Blood Cancer","05｜After the In Vivo CAR-T Boom, Does Off-the-Shelf CAR-T Still Have a Role?","06｜The Bigger Threat May Be Bispecific Antibodies, Not In Vivo CAR-T","07｜How Taiwan Should Read the Trend: Yushibo-KY and Ever Supreme as the Closest Local Angles","Conclusion｜Off-the-Shelf CAR-T Did Not Exit. It Is Finding Its Real Place."],"references":[{"title":"Original Drugnews Facebook post, Off-the-Shelf CAR-T in 2026:","source":"","date":"","url":"https://www.facebook.com/permalink.php?story_fbid=pfbid025GPiNgvtt3Bm4sXCkZLuPWfnLRJmp6FELtp6G3TCh4zV3SquoEJvzsDm1PwBykeJl&id=61568446257142"},{"title":"Caribou Biosciences pipeline, vispa-cel / CB-010 and ANTLER clinical program:","source":"","date":"","url":"https://www.cariboubio.com/pipeline/"},{"title":"Allogene ALPHA3 trial page, cema-cel for MRD-positive LBCL / DLBCL after first-line therapy:","source":"","date":"","url":"https://allogene.com/alpha3/"},{"title":"ClinicalTrials.gov, ALPHA3 study record:","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06127693"},{"title":"Wugen pipeline, WU-CART-007 allogeneic CD7-targeted CAR-T program:","source":"","date":"","url":"https://wugen.com/pipeline/"},{"title":"Wugen press release, first patients dosed in pivotal WU-CART-007 trial and previously reported response data:","source":"","date":"","url":"https://wugen.com/wugen-announces-dosing-of-first-patients-in-pivotal-trial-of-off-the-shelf-allogeneic-cd7-targeted-car-t-cell-therapy-wu-cart-007/"}],"images":[{"alt":"Off-the-shelf CAR-T workflow","url":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/figure-01.png"},{"alt":"Vispa-cel clinical signal","url":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/figure-02.png"},{"alt":"Beyond last-line rescue","url":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/figure-03.png"},{"alt":"The next cell therapy race","url":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-06）。Off-the-Shelf CAR-T in 2026: Rebounding From the Trough。https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-06-universal-car-t-2026-rebound.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}